MedTrace Logo

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy

NCT02282579 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2018-04-26

No results posted yet for this study

Summary

The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on efficacy and safety of pazopanib as a first-line therapy in practice usual for the clinical treatment of metastatic Renal Carcinoma.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Pazopanib

Non interventional study

Sponsors & Collaborators

  • Spanish Oncology Genito-Urinary Group

    lead OTHER

Principal Investigators

  • Jose Arranz, PhD · Investigator coordinator

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-02-28
Completion
2015-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02282579 on ClinicalTrials.gov